 Phase 12 Trial for Lead Candidate CFT7455, a MonoDACTM Degrader Targeting IKZF13 for the Treatment of Hematologic Malignancies, On Track for 1H 2021 Initiation Following FDA Clearance of Investigational New Drug IND 